APO-DIPYRIDAMOLE TABLET
Država: Kanada
Jezik: angleščina
Source: Health Canada
Lastnosti izdelka
(SPC)
10-08-2021
Nekateri dokumenti za ta izdelek trenutno niso na voljo, pošljete lahko zahtevo v našo stranko in obvestili vas bomo takoj, ko jih bomo lahko pridobili.
Pošlji zahtevo.
Pošlji zahtevo.
Aktivna sestavina:
DIPYRIDAMOLE
Dostopno od:
APOTEX INC
Koda artikla:
B01AC07
INN (mednarodno ime):
DIPYRIDAMOLE
Odmerek:
50MG
Farmacevtska oblika:
TABLET
Sestava:
DIPYRIDAMOLE 50MG
Pot uporabe:
ORAL
Enote v paketu:
250ML
Tip zastaranja:
Prescription
Terapevtsko območje:
MISCELLANEOUS VASODILATATING AGENTS
Povzetek izdelek:
Active ingredient group (AIG) number: 0106621002; AHFS:
Status dovoljenje:
APPROVED
Datum dovoljenje:
2021-08-12
Lastnosti izdelka
Page 1 of 18
PRODUCT MONOGRAPH
PR
APO-DIPYRIDAMOLE
DIPYRIDAMOLE TABLETS USP
25, 50, 75 AND 100 MG
PR
APO-DIPYRIDAMOLE-SC
DIPYRIDAMOLE SUGAR-COATED TABLETS USP
25, 50 AND 75 MG
CORONARY VASODILATOR
INHIBITOR OF PLATELET ADHESION AND AGGREGATION
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
DATE OF REVISION:
M9L 1T9
AUGUST 10, 2021
CONTROL NUMBER: 246833
Page 2 of 18
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
SUMMARY PRODUCT
INFORMATION......................................................................................
3
INDICATIONS AND CLINICAL USES
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND PRECAUTIONS
.............................................................................................
3
ADVERSE
REACTIONS.............................................................................................................
4
DRUG INTERACTIONS
.............................................................................................................
5
DOSAGE AND ADMINISTRATION
.............................................................................................
6
OVERDOSAGE..........................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................
6
STORAGE AND STABILITY
.......................................................................................................
7
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................................. 7
PART II: SCIENTIFIC INFORMATION
...........................................................................................
9
PHARMACEUTICAL INFORMATION
.............................................
Preberite celoten dokument
